Osteoporosis Condition Center Debuts

Published Online: Thursday, June 14, 2012

This month, we introduce a new condition center on www .PharmacyTimes.com covering osteoporosis. The condition affects approximately 1 of 5 women in the United States, and occurs when a patient’s body produces new bone more slowly than it removes old bone. As a result, falls and simple actions are more likely to result in fractures, particularly in the wrist, hip, and spine.

The condition affects men and women of all races, but women are more likely to have it. Additional risk factors include having a small body frame, family history, lowered sex hormone levels, low calcium intake, thyroid problems, consistent use of corticosteroid medications, and eating disorders. Treatment options include intravenous, nasal, and oral medications, and lifestyle changes. Pharmacists can play an important role in emphasizing the importance of medication adherence as well as preventive measures.

Some of the topics covered in the osteoporosis condition center include:

  • Indications that bisphosphonates used to prevent osteoporosis may increase the risk of fracture
  • The relationship between early menopause and increased risk of osteoporosis
  • Genetic variations associated with osteoporosis risk

Latest Articles
Mylan has announced the US launch of clozapine orally disintegrating tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical’s FazaClo.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about some safeguards pharmacists can implement.
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Latest Issues